CytomX Therapeutics Inc.

Contributing Author

Recent Articles by CytomX Therapeutics Inc.

Oct-30	CytomX Therapeutics to Report Third Quarter 2025 Financial Results on November 6, 2025 CTMX GlobeNewswire
Oct-20	CytomX Therapeutics Appoints Rachael Lester as Chief Business Officer CTMX GlobeNewswire
Aug-28	CytomX Therapeutics to Present at Upcoming September Investor Conferences CTMX GlobeNewswire
Aug-13	CytomX Therapeutics Provides Update on CX-2051 Phase 1 Study CTMX GlobeNewswire
Aug-07	CytomX Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update CTMX GlobeNewswire
Jul-31	CytomX Therapeutics to Report Second Quarter 2025 Financial Results on August 7, 2025 CTMX GlobeNewswire
May-29	CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference CTMX GlobeNewswire
May-19	CytomX Therapeutics Announces First Patient Dosed in Combination Arm of Phase 1 Study of CX-801 plus KEYTRUDA (pembrolizumab) in Patients with Metastatic Melanoma CTMX GlobeNewswire
May-12	CytomX Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock CTMX GlobeNewswire
May-12	CytomX Announces Positive Interim Data From Phase 1 Dose Escalation Study of EpCAM Antibody Drug Conjugate (CX-2051) Candidate in Patients with Advanced Colorectal Cancer (CRC) CTMX GlobeNewswire
May-12	CytomX Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update CTMX GlobeNewswire
May-05	CytomX Therapeutics to Report First Quarter 2025 Financial Results on May 12, 2025 CTMX GlobeNewswire